Last reviewed · How we verify

ASAQ Winthrop® Sanofi Aventis

Epicentre · Phase 1 active Small molecule

ASAQ Winthrop® Sanofi Aventis is a Antimalarial Small molecule drug developed by Epicentre. It is currently in Phase 1 development for Malaria. Also known as: COARSUCAM 25 mg/67,5 mg, COARSUCAM 50 mg/135 mg, COARSUCAM 100 mg/270 mg.

Artemisinin and Amodiaquine combination

Artemisinin and Amodiaquine combination Used for Malaria.

At a glance

Generic nameASAQ Winthrop® Sanofi Aventis
Also known asCOARSUCAM 25 mg/67,5 mg, COARSUCAM 50 mg/135 mg, COARSUCAM 100 mg/270 mg
SponsorEpicentre
Drug classAntimalarial
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 1

Mechanism of action

Artemisinin is a peroxide-containing endoperoxide compound that exerts its antimalarial activity through the generation of free radicals, which damage the parasite's cell membrane and proteins. Amodiaquine is a 4-aminoquinoline antimalarial drug that works by interfering with the parasite's heme detoxification pathway.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ASAQ Winthrop® Sanofi Aventis

What is ASAQ Winthrop® Sanofi Aventis?

ASAQ Winthrop® Sanofi Aventis is a Antimalarial drug developed by Epicentre, indicated for Malaria.

How does ASAQ Winthrop® Sanofi Aventis work?

Artemisinin and Amodiaquine combination

What is ASAQ Winthrop® Sanofi Aventis used for?

ASAQ Winthrop® Sanofi Aventis is indicated for Malaria.

Who makes ASAQ Winthrop® Sanofi Aventis?

ASAQ Winthrop® Sanofi Aventis is developed by Epicentre (see full Epicentre pipeline at /company/epicentre).

Is ASAQ Winthrop® Sanofi Aventis also known as anything else?

ASAQ Winthrop® Sanofi Aventis is also known as COARSUCAM 25 mg/67,5 mg, COARSUCAM 50 mg/135 mg, COARSUCAM 100 mg/270 mg.

What drug class is ASAQ Winthrop® Sanofi Aventis in?

ASAQ Winthrop® Sanofi Aventis belongs to the Antimalarial class. See all Antimalarial drugs at /class/antimalarial.

What development phase is ASAQ Winthrop® Sanofi Aventis in?

ASAQ Winthrop® Sanofi Aventis is in Phase 1.

What are the side effects of ASAQ Winthrop® Sanofi Aventis?

Common side effects of ASAQ Winthrop® Sanofi Aventis include Nausea, Vomiting, Diarrhea, Abdominal pain, Headache.

Related